---
title: "Dexcom’s $750 Million 2025 Buyback Plan Faces Uncertain Execution and Limited Assurance of Shareholder Value"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275970360.md"
description: "Dexcom has announced a $750 million share repurchase program for 2025, but its execution may be uncertain due to market volatility and competing capital needs. There is no guarantee that the buyback will enhance long-term shareholder value. Despite this, Wall Street maintains a Strong Buy consensus on DXCM stock, with 17 Buys, 1 Sell, and 3 Holds."
datetime: "2026-02-14T06:00:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275970360.md)
  - [en](https://longbridge.com/en/news/275970360.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275970360.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275970360.md) | [繁體中文](https://longbridge.com/zh-HK/news/275970360.md)


# Dexcom’s $750 Million 2025 Buyback Plan Faces Uncertain Execution and Limited Assurance of Shareholder Value

Dexcom (DXCM) has disclosed a new risk, in the Share Price & Shareholder Rights category.

### Valentine's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Dexcom’s 2025 Share Repurchase Program, authorized for up to $750 million through June 30, 2026, may not be fully executed and offers no assurance of enhancing long‑term shareholder value. External factors such as market volatility, competing capital allocation needs, and discretionary timing could limit repurchases or result in buybacks at prices that fail to improve EPS or sustain the stock price.

Overall, Wall Street has a Strong Buy consensus rating on DXCM stock based on 17 Buys, 1 Sell and 3 Holds.

To learn more about Dexcom’s risk factors, click here.

### Related Stocks

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [DexCom, Inc. (DXCM.US)](https://longbridge.com/en/quote/DXCM.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [BUZZ-MiniMed rises as FDA clears smartphone‑controlled insulin pump](https://longbridge.com/en/news/279614092.md)
- [Trevi Therapeutics Maps Phase III Path and Runway](https://longbridge.com/en/news/279703997.md)
- [Aethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying Equity](https://longbridge.com/en/news/279446168.md)
- [Bluejay Weighs Proposed Therapeutic Acquisition, Reaffirms Symphony Focus](https://longbridge.com/en/news/279245032.md)
- [10:10 ETPicarro Launches PI2124 Hydrogen Peroxide Analyzer to Improve VHP Monitoring in Pharmaceutical Manufacturing](https://longbridge.com/en/news/279619247.md)